Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Susanna Banerjee highlighted that the NRG19 trial failed to establish non-inferiority when comparing letrozole monotherapy against standard chemotherapy followed by letrozole. Even though low-grade serous tumors express ER and PR, receptor levels do not predict response, meaning chemotherapy remains necessary.

Related Insights

Current data does not support replacing chemotherapy with CDK4/6 inhibitors in the neoadjuvant setting for high-risk, ER-positive breast cancer. The Carabella study showed chemotherapy achieved better pathological responses than letrozole plus abemaciclib, particularly in premenopausal women. This indicates these targeted agents are additive to, not a replacement for, standard chemotherapy.

The landmark GY019 trial confirmed that letrozole alone is inferior to the standard of chemotherapy followed by letrozole maintenance. This was a surprising result for a chemo-resistant tumor, solidifying the need for chemotherapy in the adjuvant setting despite its limited effectiveness.

A retrospective analysis of the MA27 trial suggests patients with invasive lobular cancer have worse outcomes with exemestane. This is attributed to an androgenic metabolite, prompting experts to prefer anastrozole or letrozole for this specific histological subtype.

Counterintuitively, the SOFT trial showed pre-menopausal women with BCI-low tumors (less driven by estrogen receptors) derived more benefit from an aromatase inhibitor (AI) plus ovarian suppression compared to tamoxifen. This suggests the most aggressive endocrine therapy is crucial for biologically aggressive, less ER-sensitive cancers.

The SET assay, measuring estrogen receptor activity, re-analyzed the NSABP B42 trial and found a 'very high SET' subgroup. This group experienced a massive 17% absolute improvement in 10-year breast cancer-free interval with extended letrozole, unmasking a profound benefit that was diluted in the overall trial results.

In low-grade, recurrent endometrial cancer, patients who show stable or progressive disease on chemotherapy can surprisingly respond to hormonal therapies like progesterone. Although the response may be slow, it highlights an important, potentially overlooked option for this specific patient population.

Counterintuitively, in premenopausal women on ovarian suppression, the more potent endocrine therapy (Aromatase Inhibitor) provided the most benefit over Tamoxifen in BCI-Low tumors. These tumors are less ER-driven, suggesting other pathways make them vulnerable to maximal estrogen deprivation.

Susanna Banerjee shared that the single-arm Chameleon trial evaluates upfront avutometinib, defactinib, and letrozole to downsize bulky or inoperable disease. Because low-grade serous cancer responds poorly to frontline chemotherapy, targeted shrinking aims to give advanced patients the opportunity to undergo complete surgical resection.

While the LADERA study showed a benefit for oral SERD gerodestrant over standard endocrine therapy, its applicability is questionable. In the metastatic setting, adding an oral SERD to a CDK inhibitor did not show a statistically significant benefit over an AI plus CDK, raising doubts about its added value in the adjuvant CDK era.

Unlike tamoxifen, oral SERDs likely cannot be used as a monotherapy in premenopausal women. The pre-CoAbera trial failed to show gerodestrant alone was sufficient and was associated with ovarian cysts and higher estradiol. This suggests ovarian function suppression (OFS) is a necessary partner for oral SERDs to be effective in this younger patient population.